{"disease":{"id":"richter-transformation","name":"richter transformation"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05107674","title":"A Study of NX-1607 in Adults With Advanced Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":345,"lead_sponsor_name":"Nurix Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04792489","title":"DALY II USA/ MB-CART2019.1 for DLBCL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":248,"lead_sponsor_name":"Miltenyi Biomedicine GmbH","has_results":false},{"nct_id":"NCT05458297","title":"A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":223,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT03162536","title":"A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":190,"lead_sponsor_name":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","has_results":false},{"nct_id":"NCT05294731","title":"Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":146,"lead_sponsor_name":"BeiGene","has_results":false},{"nct_id":"NCT04771572","title":"Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Newave Pharmaceutical Inc","has_results":false},{"nct_id":"NCT03833180","title":"A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":91,"lead_sponsor_name":"VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":false},{"nct_id":"NCT06043674","title":"Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Christine Ryan","has_results":false},{"nct_id":"NCT04305444","title":"Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":55,"lead_sponsor_name":"Zhejiang DTRM Biopharma","has_results":false},{"nct_id":"NCT04992377","title":"R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT02138786","title":"Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":27,"lead_sponsor_name":"Karyopharm Therapeutics Inc","has_results":true},{"nct_id":"NCT04806035","title":"Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":21,"lead_sponsor_name":"TG Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05537766","title":"Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":19,"lead_sponsor_name":"Kite, A Gilead Company","has_results":true},{"nct_id":"NCT03778073","title":"Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":18,"lead_sponsor_name":"TG Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07168486","title":"CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas","phase":"PHASE1","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":15,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":false},{"nct_id":"NCT06936943","title":"ONO-4538 Study in Patients With Richter's Transformation","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":14,"lead_sponsor_name":"Ono Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03121534","title":"Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT03153514","title":"Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"German CLL Study Group","has_results":false}],"total":18},"guidelines":[],"source":"Drug Landscape verified database"}